The Marshfield Clinic Research Institute, a division of Marshfield Clinic Inc and a private medical research institute in Wisconsin, has been added to TriNetX network, a collaborative research network, representing healthcare organisations and health data partners across the world, it was reported on Monday.
Marshfield has joined the network to increase clinical trial opportunities for its largely rural patient population.
Dr Narayana S Murali, executive director of Marshfield Clinic Inc, said, 'Marshfield Clinic Research Institute is a leader in clinical trials and research. Being part of the TriNetX network increases our opportunities to participate in high-impact studies and bring the best care to our patients. We anticipate increased opportunities for our geographically dispersed patient population to participate in clinical trials that can make a difference in their health.'
The Marshfield Clinic Health System offers care to a rural population in the United States and is one of only a few large independent non-profit medical clinics in the country. It is an integrated health system serving Wisconsin with over 10,000 employees including more than 1,200 providers across 90 specialties, a health plan, and research and education programs. The centre employs research nurses, study coordinators, and technical support staff that are organised into two programs (multispecialty and oncology).
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study
Precision Epigenomics partners with TruDiagnostic
Modalis partners with Ginkgo Bioworks
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Algiax Pharmaceuticals reveals update on chronic neuropathic pain study